---
title: "Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290686799.md"
description: "Cognition Therapeutics received FDA feedback aligning on key elements for a pivotal Phase 3 trial of zervimesine in DLB psychosis. The FDA indicated that DLB psychosis could support approval, clarifying the path to an NDA. The registrational program is expected to start in mid-2027, testing once-daily oral zervimesine versus placebo over nine months."
datetime: "2026-06-24T11:30:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290686799.md)
  - [en](https://longbridge.com/en/news/290686799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290686799.md)
---

# Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosis

-   Cognition Therapeutics received FDA written feedback aligning on key elements of a pivotal Phase 3 study of zervimesine in DLB psychosis. \* The FDA agreed DLB psychosis could support approval, setting a clearer path toward an NDA. \* The registrational program is expected to start in mid-2027, testing once-daily oral zervimesine versus placebo over nine months. \* Prior Phase 2 SHIMMER results were already presented, showing improvement in psychosis symptoms versus placebo without detailing specific measurements. \* Additional Phase 2 analyses are scheduled for presentation in July at the Alzheimer’s Association International Conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240730PRIMZONEFULLFEED9751681) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CGTX.US](https://longbridge.com/en/quote/CGTX.US.md)

## Related News & Research

- [Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website](https://longbridge.com/en/news/292481427.md)
- [Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027](https://longbridge.com/en/news/288717735.md)
- [ACADIA issues press release on FDA Fast Track designation for remlifanserin in Alzheimer’s disease psychosis](https://longbridge.com/en/news/293219067.md)
- [Why Cognition bought Poke: AI personality is becoming a competitive advantage](https://longbridge.com/en/news/293785961.md)
- [13:00 ETIcarus Recovery Center Names Dr. Lauren T. Bonner Medical Director and Juliet Dennis Clinical Director](https://longbridge.com/en/news/293369786.md)